Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer

Treatment Outcomes ◽

Castration Resistant ◽

Recombination Repair ◽

Repair Genes

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Annals of Oncology ◽

10.1093/annonc/mdz446.007 ◽

2019 ◽

Vol 30 ◽

pp. ix188-ix189 ◽

Cited By ~ 3

Author(s):

S.K. Sandhu ◽

M. Hussain ◽

J. Mateo ◽

K. Fizazi ◽

F. Saad ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Iii ◽

Castration Resistant ◽

Recombination Repair ◽

Phase Iii Study ◽

Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer

Cancer Biology & Therapy ◽

10.1080/15384047.2020.1809913 ◽

2020 ◽

Vol 21 (10) ◽

pp. 884-887

Author(s):

Vincent Chau ◽

Ravi A. Madan ◽

William D. Figg

Keyword(s):

Prostate Cancer ◽

Castration Resistant ◽

624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound

Annals of Oncology ◽

10.1016/j.annonc.2020.08.883 ◽

2020 ◽

Vol 31 ◽

pp. S515-S516

Author(s):

G. Roubaud ◽

M. Ozguroglu ◽

N. Penel ◽

N. Matsubara ◽

N. Mehra ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant ◽

Recombination Repair ◽

Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations

Annals of Oncology ◽

10.1093/annonc/mdy284.002 ◽

2018 ◽

Vol 29 ◽

pp. viii272 ◽

Cited By ~ 25

Author(s):

W. Abida ◽

A.H. Bryce ◽

N.J. Vogelzang ◽

R.J. Amato ◽

I. Percent ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Preliminary Results ◽

Castration Resistant ◽

Recombination Repair ◽

73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.08.353 ◽

2021 ◽

Vol 32 ◽

pp. S387

Author(s):

E. Yu ◽

J.M. Piulats ◽

G. Gravis ◽

P. Fong ◽

T. Todenhöfer ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant ◽

Biomarker Analysis ◽

654P Real-world treatment (Tx) patterns in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm+)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.913 ◽

2020 ◽

Vol 31 ◽

pp. S531-S532

Author(s):

N. Shore ◽

R. Ionescu-Ittu ◽

F. Laliberté ◽

L. Yang ◽

A. Gayle ◽

...

Keyword(s):

Prostate Cancer ◽

Real World ◽

Castration Resistant ◽

Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Targeted Oncology ◽

10.1007/s11523-021-00837-y ◽

2021 ◽

Vol 16 (5) ◽

pp. 613-623

Author(s):

Rachel Evans ◽

Neil Hawkins ◽

Pascale Dequen-O’Byrne ◽

Charles McCrea ◽

Dominic Muston ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Treatment Switching ◽

Castration Resistant ◽

Recombination Repair ◽

The Impact

Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions

Oncotarget ◽

10.18632/oncotarget.28015 ◽

2021 ◽

Author(s):

Rodney J. Scott ◽

Anurag Mehta ◽

Gabriel S. Macedo ◽

Pavel S. Borisov ◽

Ravindran Kanesvaran ◽

...

Keyword(s):

Prostate Cancer ◽

Genetic Testing ◽

Castration Resistant ◽

PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

Annals of Oncology ◽

10.1093/annonc/mdz394.039 ◽

2019 ◽

Vol 30 ◽

pp. v881-v882 ◽

Cited By ~ 36

Author(s):

M. Hussain ◽

J. Mateo ◽

K. Fizazi ◽

F. Saad ◽

N.D. Shore ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Iii ◽

Castration Resistant ◽

Recombination Repair ◽

Phase Iii Study ◽

Final overall survival (OS) analysis of PROfound: olaparib vs physician's choice of enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

10.26226/morressier.5f4d10acb0f0f3411b83096d ◽

2020 ◽

Author(s):

Antoine Theiry-Vuillemin

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Castration Resistant ◽

Recombination Repair ◽